MX9400911A - Uso de inhibidores de ornitina aminotransferasa enel tratamiento de la demencia del tipo de alzheimer. - Google Patents

Uso de inhibidores de ornitina aminotransferasa enel tratamiento de la demencia del tipo de alzheimer.

Info

Publication number
MX9400911A
MX9400911A MX9400911A MX9400911A MX9400911A MX 9400911 A MX9400911 A MX 9400911A MX 9400911 A MX9400911 A MX 9400911A MX 9400911 A MX9400911 A MX 9400911A MX 9400911 A MX9400911 A MX 9400911A
Authority
MX
Mexico
Prior art keywords
treatment
alzheimer
amnotransferase
ornitine
inhibitors
Prior art date
Application number
MX9400911A
Other languages
English (en)
Inventor
Nikolaus Seiler
Jean-Bernard Ducep
Karin C Jund
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of MX9400911A publication Critical patent/MX9400911A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al nuevo uso de los derivados de ornitina 5-substituídos, para la preparación de una composición farmaceútica para el tratamiento de la demencia del tipo de alzheimer.
MX9400911A 1993-02-05 1994-02-04 Uso de inhibidores de ornitina aminotransferasa enel tratamiento de la demencia del tipo de alzheimer. MX9400911A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93400303A EP0609630A1 (en) 1993-02-05 1993-02-05 Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of Alzheimer's disease

Publications (1)

Publication Number Publication Date
MX9400911A true MX9400911A (es) 1994-08-31

Family

ID=8214677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9400911A MX9400911A (es) 1993-02-05 1994-02-04 Uso de inhibidores de ornitina aminotransferasa enel tratamiento de la demencia del tipo de alzheimer.

Country Status (14)

Country Link
US (1) US5637768A (es)
EP (2) EP0609630A1 (es)
JP (1) JPH08506577A (es)
AU (1) AU682330B2 (es)
CA (1) CA2152796A1 (es)
FI (1) FI953725A0 (es)
HU (1) HUT73173A (es)
IL (1) IL107737A (es)
MX (1) MX9400911A (es)
NO (1) NO953072L (es)
NZ (2) NZ258461A (es)
TW (1) TW383337B (es)
WO (1) WO1994017795A1 (es)
ZA (1) ZA938836B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211602B2 (en) * 2001-11-16 2007-05-01 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP1448183A2 (en) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
CN111362828A (zh) * 2020-03-30 2020-07-03 山西医科大学 一种18f标记的氟丙酰化鸟氨酸及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE77367T1 (de) * 1988-02-05 1992-07-15 Merrell Dow Pharma 5-substituierte ornithin-derivate.

Also Published As

Publication number Publication date
NO953072D0 (no) 1995-08-04
ZA938836B (en) 1994-08-02
IL107737A (en) 1998-12-27
FI953725A (fi) 1995-08-04
NO953072L (no) 1995-08-04
HUT73173A (en) 1996-06-28
IL107737A0 (en) 1994-02-27
CA2152796A1 (en) 1994-08-18
JPH08506577A (ja) 1996-07-16
TW383337B (en) 2000-03-01
NZ258461A (en) 1997-03-24
FI953725A0 (fi) 1995-08-04
AU5614394A (en) 1994-08-29
AU682330B2 (en) 1997-10-02
EP0682515A1 (en) 1995-11-22
EP0609630A1 (en) 1994-08-10
WO1994017795A1 (en) 1994-08-18
HU9502320D0 (en) 1996-05-28
NZ280983A (en) 1997-07-27
US5637768A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ECSP088246A (es) Nuevos derivados de benzotiazolona
SE9904505D0 (sv) Novel compounds
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
UY27516A1 (es) Bencimidazoles
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
HN2002000300A (es) Nuevos derivados de piperazina
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
AR047070A1 (es) Derivados de difenilazetidona
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ES2154318T3 (es) Agentes antitromboticos.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
MX9300399A (es) Derivados heterotriciclicos.
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
HN2001000235A (es) Derivados puentes de piperazina
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica